Suren N. Sehgal

7.0k citations

58 papers · 5.5k indexed · 4 hit papers · h-index 28

Molecular Biology top 2%
Transplantation top 0.2%
Surgery top 5%
Immunology top 5%
Oncology top 5%

Co-authors: Claude Vézina Hinton J. Baker C. P. Eng Joseph Chang Laurel M. Adams Barry D. Kahan Timothy D. Ocain Katherine L. Molnar-Kimber
Topics: Signaling Pathways in Disease (20 papers)Renal Transplantation Outcomes and Treatments (8 papers)Synthesis and Biological Evaluation (8 papers)
Cited by: Transplantation Physiology Aging
Journals: Blood The Journal of Immunology Biochemical and Biophysical Research Communications
Partner nations: United States Canada Japan

In The Last Decade

Suren N. Sehgal

58 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.

1975 1.2k citations Suren N. Sehgal et al. profile →
Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

1975 724 citations Suren N. Sehgal et al. profile →
Sirolimus: its discovery, biological properties, and mechanism of action

2003 580 citations Suren N. Sehgal Transplantation Proceedings profile →
Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

1998 562 citations Suren N. Sehgal Clinical Biochemistry profile →

Peers

Countries citing papers authored by Suren N. Sehgal

Since Specialization

Citations

This map shows the geographic impact of Suren N. Sehgal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suren N. Sehgal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suren N. Sehgal more than expected).

Fields of papers citing papers by Suren N. Sehgal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suren N. Sehgal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suren N. Sehgal. The network helps show where Suren N. Sehgal may publish in the future.

Co-authorship network of co-authors of Suren N. Sehgal

This figure shows the co-authorship network connecting the top 25 collaborators of Suren N. Sehgal. A scholar is included among the top collaborators of Suren N. Sehgal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suren N. Sehgal. Suren N. Sehgal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	COMPROMISED KIDNEY GRAFT REJECTION RESPONSE IN VERVET MONKEYS AFTER WITHDRAWAL OF IMMUNOSUPPRESSANTS TACROLIMUS AND SIROLIMUS1 2000 ·Transplantation ·Huifang Chen,Junzheng Peng,Hongyu Luo,Martine Loubeau,Xiaochun Wan,Dasheng Xu,Shijie Qi,Minh Diem Vu,Pierre Daloze,William E. Fitzsimmons,Ihor Bekersky,(unknown),Suren N. Sehgal,Jiangping Wu	25
2	STIMULATED RESPONSE OF PERIPHERAL LYMPHOCYTES MAY DISTINGUISH CYCLOSPORINE EFFECT IN RENAL TRANSPLANT RECIPIENTS RECEIVING A CYCLOSPORINE+RAPAMYCIN REGIMEN1 2000 ·Transplantation ·Rakesh Sindhi,Mariano F. LaVia,Emily E. Paulling,John McMichael,Gilbert J. Burckart,Susan E. Shaw,(unknown),Robert S. Livingston,Suren N. Sehgal,Jonathan S. Jaffe	83
3	EFFECT OF TACROLIMUS (FK506) AND SIROLIMUS (RAPAMYCIN) MONO- AND COMBINATION THERAPY IN PROLONGATION OF RENAL ALLOGRAFT SURVIVAL IN THE MONKEY1 2000 ·Transplantation ·Shijie Qi,Dasheng Xu,Junzheng Peng,Minh Diem Vu,Jiangping Wu,Ihor Bekersky,William E. Fitzsimmons,(unknown),Suren N. Sehgal,Pierre Daloze,Huifang Chen	62
4	Manipulation of the C(22)-C(27) region of rapamycin: Stability issues and biological implications 1999 ·Bioorganic & Medicinal Chemistry Letters ·Frances C. Nelson,Shawn J. Stachel,C. P. Eng,Suren N. Sehgal	21
5	High Local Production of Nitric Oxide As a Possible Mechanism by Which Rapamycin Prevents Transplant Arteriosclerosis 1998 ·Transplantation Proceedings ·Si M. Pham,L.L Shears,Nobuyoshi Kawaharada,S Li,Raman Venkataramanan,Suren N. Sehgal	27
6	Combined effect of rapamycin and FK 506 in prolongation of small bowel graft survival in the mouse 1998 ·Transplantation Proceedings ·(unknown),Sihua Qi,Da-Zhong Xu,William E. Fitzsimmons,I Bekersky,Suren N. Sehgal,Pierre Daloze	15
7	Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progressionbreakdown → 1998 ·Clinical Biochemistry ·Suren N. Sehgal	562
8	TACROLIMUS (FK506) AND SIROLIMUS (RAPAMYCIN) IN COMBINATION ARE NOT ANTAGONISTIC BUT PRODUCE EXTENDED GRAFT SURVIVAL IN CARDIAC TRANSPLANTATION IN THE RAT1,2 1997 ·Transplantation ·Minh Diem Vu,Shijie Qi,Dasheng Xu,Jiangping Wu,William E. Fitzsimmons,Suren N. Sehgal,Louis Dumont,Stéphan Busque,Pierre Daloze,Huifang Chen	84
9	THERAPEUTIC BLOOD LEVELS OF SIROLIMUS (RAPAMYCIN) IN THE ALLOGRAFTED RAT 1996 ·Transplantation ·John F. DiJoseph,Eric Fluhler,(unknown),Michele A. Sharr,Suren N. Sehgal	33
10	Sirolimus (rapamycin) inhibits mitogen-induced stimulation of protein synthesis in primary lymphocytes 1995 ·Inflammation Research ·(unknown),(unknown),Suren N. Sehgal	4
11	Rapamycin (sirolimus, rapamune) 1995 ·Current Opinion in Nephrology & Hypertension ·Suren N. Sehgal,Joseph S. Camardo,Joseph A. Scarola,(unknown)	56
12	Prolongation Of Renal Allograft Survival In A Large Animal Model By Oral Rapamycin Monotherapy 1995 ·Transplantation ·Darla K. Granger,John W. Cromwell,(unknown),Joseph J. Goswitz,(unknown),(unknown),Suren N. Sehgal,Daniel M. Canafax,Arthur J. Matas	4
13	Comparison of effects of sirolimus on cytokine dependent and cytokine independent proliferation 1995 ·Inflammation Research ·Katherine L. Molnar-Kimber,(unknown),(unknown),Haoze Chen,Suren N. Sehgal	2
14	Sub-therapeutic doses of sirolimus and cyclosporin A in combination reduce SLE pathologies in the MRL mouse 1995 ·Inflammation Research ·(unknown),Terri Cummons,(unknown),Suren N. Sehgal	6
15	Consensus Guidelines for Therapeutic Drug Monitoring of Rapamycin: Report of the Consensus Panel 1995 ·Therapeutic Drug Monitoring ·Randall W. Yatscoff,Roger L. Boeckx,David W. Holt,Barry D. Kahan,Donald F. LeGatt,Suren N. Sehgal,Steven J. Soldin,Kimberly L. Napoli,C. R. Stiller	67
16	Renal effects of rapamycin in the spontaneously hypertensive rat 1994 ·Transplant International ·John F. DiJoseph,Michael J. Mihatsch,Suren N. Sehgal	27
17	Rapamycin Prolongs Survival and Arrests Pathophysiologic Changes in Murine Systemic Lupus Erythematosus 1994 ·Arthritis & Rheumatism ·(unknown),Laurel M. Adams,Suren N. Sehgal	149
18	Rapamycin's Inhibition of Thymocyte Proliferation, Unlike That of Cyclosporin A or Prednisolone, Is Not Associated with Cytotoxicity 1993 ·Annals of the New York Academy of Sciences ·(unknown),(unknown),Robert Caccese,Chien‐Chang Shen,Suren N. Sehgal	4
19	Effects of Orally Administered Rapamycin in Animal Models of Arthritis and Other Autoimmune Diseases 1993 ·Annals of the New York Academy of Sciences ·Richard P. Carlson,(unknown),Robert Caccese,(unknown),Suren N. Sehgal	42
20	FK506 and rapamycin: novel pharmacological probes of the immune response 1991 ·Trends in Pharmacological Sciences ·Joseph Chang,Suren N. Sehgal,(unknown)	74

About Suren N. Sehgal

Suren N. Sehgal is a scholar working on Transplantation, Toxicology and Immunology, having authored 58 papers that have together received 5.5k indexed citations. Recurring topics across this work include Signaling Pathways in Disease (20 papers), Renal Transplantation Outcomes and Treatments (8 papers) and Synthesis and Biological Evaluation (8 papers). The work is most often cited by research in Transplantation (1.3k citations), Physiology (240 citations) and Aging (79 citations). Suren N. Sehgal has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Claude Vézina, Hinton J. Baker, C. P. Eng, Joseph Chang, Laurel M. Adams, Barry D. Kahan, Timothy D. Ocain, Katherine L. Molnar-Kimber, Barry M. Weichman and John F. DiJoseph. Their work appears in journals such as Blood, The Journal of Immunology and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact